ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Selectivity and Anti-Parkinson’s Potential of Thiadiazolidinone RGS4 Inhibitors

View Author Information
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States,
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824, United States
§ Department of Pharmacy and Pharmacology, University of Bath, Bath, U.K.
Section of Pharmacology, Department of Medical Science, University of Ferrara, Ferrara, Italy 44121
National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina 27599, United States
*Department of Pharmacology & Toxicology, Michigan State University, B440 Life Sciences, 1355 Bogue St., East Lansing, MI 48824. Phone: 517 353-7145. Fax: 517 353-8915. E-mail: [email protected]
Cite this: ACS Chem. Neurosci. 2015, 6, 6, 911–919
Publication Date (Web):April 6, 2015
Copyright © 2015 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    Many current therapies target G protein coupled receptors (GPCR), transporters, or ion channels. In addition to directly targeting these proteins, disrupting the protein–protein interactions that localize or regulate their function could enhance selectivity and provide unique pharmacologic actions. Regulators of G protein signaling (RGS) proteins, especially RGS4, play significant roles in epilepsy and Parkinson’s disease. Thiadiazolidinone (TDZD) inhibitors of RGS4 are nanomolar potency blockers of the biochemical actions of RGS4 in vitro. Here, we demonstrate the substantial selectivity (8- to >5000-fold) of CCG-203769 for RGS4 over other RGS proteins. It is also 300-fold selective for RGS4 over GSK-3β, another target of this class of chemical scaffolds. It does not inhibit the cysteine protease papain at 100 μM. CCG-203769 enhances Gαq-dependent cellular Ca2+ signaling in an RGS4-dependent manner. TDZD inhibitors also enhance Gαi-dependent δ-OR inhibition of cAMP production in SH-SY-5Y cells, which express endogenous receptors and RGS4. Importantly, CCG-203769 potentiates the known RGS4 mechanism of Gαi-dependent muscarinic bradycardia in vivo. Furthermore, it reverses raclopride-induced akinesia and bradykinesia in mice, a model of some aspects of the movement disorder in Parkinson’s disease. A broad assessment of compound effects revealed minimal off-target effects at concentrations necessary for cellular RGS4 inhibition. These results expand our understanding of the mechanism and specificity of TDZD RGS inhibitors and support the potential for therapeutic targeting of RGS proteins in Parkinson’s disease and other neural disorders.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    Jump To

    Brief characterization of the M3-R4 Flp-in cell line. This material is available free of charge via the Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 39 publications.

    1. Wuqiang Wen, Hongxuan Cao, Yunyuan Huang, Jie Tu, Chen Wan, Jian Wan, Xinya Han, Han Chen, Jiaqi Liu, Li Rao, Chen Su, Chao Peng, Chunquan Sheng, Yanliang Ren. Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of Candidiasis. Journal of Medicinal Chemistry 2022, 65 (3) , 2656-2674.
    2. Vincent S. Shaw, Hossein Mohammadiarani, Harish Vashisth, Richard R. Neubig. Differential Protein Dynamics of Regulators of G-Protein Signaling: Role in Specificity of Small-Molecule Inhibitors. Journal of the American Chemical Society 2018, 140 (9) , 3454-3460.
    3. Christopher R. Bodle, Duncan I. Mackie, Michael P. Hayes, Josephine H Schamp, Michael R. Miller, Michael D. Henry, Jonathan A. Doorn, Jon C. D. Houtman, Michael A. James, and David L. Roman . Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines. Journal of Natural Products 2017, 80 (7) , 1992-2000.
    4. Pauline Beckers, Pierre J. Doyen, Emmanuel Hermans. Modulation of Type 5 Metabotropic Glutamate Receptor-Mediated Intracellular Calcium Mobilization by Regulator of G Protein Signaling 4 (RGS4) in Cultured Astrocytes. Cells 2024, 13 (4) , 291.
    5. Samantha M. McNeill, Peishen Zhao. The roles of RGS proteins in cardiometabolic disease. British Journal of Pharmacology 2023, 15
    6. Clarissa A. Pisanò, Daniela Mercatelli, Martina Mazzocchi, Alberto Brugnoli, Ilaria Morella, Stefania Fasano, Nurulain T. Zaveri, Riccardo Brambilla, Gerard W. O'Keeffe, Richard R. Neubig, Michele Morari. Regulator of G‐Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l ‐Dopa‐induced dyskinesia. British Journal of Pharmacology 2023, 180 (7) , 927-942.
    7. Valentin K. Gribkoff, Leonard K. Kaczmarek. The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders. 2023, 255-285.
    8. Kathy Yuen Yee Chan, Po Yee Chung, Chi Zhang, Ellen Ngar Yun Poon, Alex Wing Kwan Leung, Kam Tong Leung. R4 RGS proteins as fine tuners of immature and mature hematopoietic cell trafficking. Journal of Leukocyte Biology 2022, 112 (4) , 785-797.
    9. Kaijiao Hu, Longbao Lv, Hui Huang, Guangnian Yin, Jie Gao, Jianping Liu, Yaying Yang, Wenxin Zeng, Yan Chen, Ni Zhang, Feiyan Zhang, Yuhua Ma, Feilan Chen. A Novel Tree Shrew Model of Chronic Experimental Autoimmune Uveitis and Its Disruptive Application. Frontiers in Immunology 2022, 13
    10. Wallace K. B. Chan, Debarati DasGupta, Heather A. Carlson, John R. Traynor. Mixed‐solvent molecular dynamics simulation‐based discovery of a putative allosteric site on regulator of G protein signaling 4. Journal of Computational Chemistry 2021, 42 (30) , 2170-2180.
    11. Nathalie Fuentes, Morgan McCullough, Reynold A. Panettieri, Kirk M. Druey. RGS proteins, GRKs, and beta-arrestins modulate G protein-mediated signaling pathways in asthma. Pharmacology & Therapeutics 2021, 223 , 107818.
    12. Justin W. Nicholatos, Joost Groot, Shekhar Dhokai, David Tran, Lori Hrdlicka, Thomas M. Carlile, Melissa Bennion, Isin Dalkilic-Liddle, Warren D. Hirst, Andreas Weihofen. SCD Inhibition Protects from α-Synuclein-Induced Neurotoxicity But Is Toxic to Early Neuron Cultures. eneuro 2021, 8 (4) , ENEURO.0166-21.2021.
    13. Christine Fok, Milan Bogosanovic, Madhavi Pandya, Ravindra Telang, Peter R. Thorne, Srdjan M. Vlajkovic. Regulator of G Protein Signalling 4 (RGS4) as a Novel Target for the Treatment of Sensorineural Hearing Loss. International Journal of Molecular Sciences 2021, 22 (1) , 3.
    14. Katelin E. Ahlers-Dannen, Mackenzie M. Spicer, Rory A. Fisher. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson’s Disease. Molecular Pharmacology 2020, 98 (6) , 730-738.
    15. Nicolas B. Senese, Ram Kandasamy, Kelsey E. Kochan, John R. Traynor. Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management. Frontiers in Molecular Neuroscience 2020, 13
    16. Patricio Atanes, Shanta J. Persaud. GPCR targets in type 2 diabetes. 2020, 367-391.
    17. Joseph B. O’Brien, Joshua C. Wilkinson, David L. Roman. Regulator of G-protein signaling (RGS) proteins as drug targets: Progress and future potentials. Journal of Biological Chemistry 2019, 294 (49) , 18571-18585.
    18. Vincent S. Shaw, Mohammadjavad Mohammadi, Josiah A. Quinn, Harish Vashisth, Richard R. Neubig. An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19. Molecular Pharmacology 2019, 96 (6) , 683-691.
    19. Mohammadjavad Mohammadi, Hossein Mohammadiarani, Vincent S. Shaw, Richard R. Neubig, Harish Vashisth. Interplay of cysteine exposure and global protein dynamics in small‐molecule recognition by a regulator of G‐protein signaling protein. Proteins: Structure, Function, and Bioinformatics 2019, 87 (2) , 146-156.
    20. Nicolas B. Senese, Mark M. Rasenick, John R. Traynor. The Role of G-proteins and G-protein Regulating Proteins in Depressive Disorders. Frontiers in Pharmacology 2018, 9
    21. Nicolas B. Senese, Max Oginsky, Richard R. Neubig, Carrie Ferrario, Emily M. Jutkiewicz, John R. Traynor. Role of hippocampal 5-HT1A receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive Gαi2 protein. Neuropharmacology 2018, 141 , 296-304.
    22. Boyd R. Rorabaugh, Madison J. Rose, Thorne S. Stoops, Allison A. Stevens, Sarah L. Seeley, Manoranjan S. D'Souza. Regulators of G-protein signaling 2 and 4 differentially regulate cocaine-induced rewarding effects. Physiology & Behavior 2018, 195 , 9-19.
    23. Katherine E. Squires, Carolina Montañez-Miranda, Rushika R. Pandya, Matthew P. Torres, John R. Hepler, . Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease. Pharmacological Reviews 2018, 70 (3) , 446-474.
    24. Christopher R. Bodle, Josephine H. Schamp, Joseph B. O’Brien, Michael P. Hayes, Meng Wu, Jonathan A. Doorn, David L. Roman. Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures. SLAS Discovery 2018, 23 (4) , 363-374.
    25. Mohammed Alqinyah, Shelley B. Hooks. Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins. Cellular Signalling 2018, 42 , 77-87.
    26. Robert Newton. Regulators of G-Protein Signaling as Asthma Therapy?. American Journal of Respiratory Cell and Molecular Biology 2018, 58 (1) , 7-9.
    27. Amer Ashrafi, Pierre Garcia, Heike Kollmus, Klaus Schughart, Antonio Del Sol, Manuel Buttini, Enrico Glaab. Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease. Neurobiology of Aging 2017, 58 , 30-33.
    28. Christopher R. Bodle, Michael P. Hayes, Joseph B. O'Brien, David L. Roman. Development of a bimolecular luminescence complementation assay for RGS: G protein interactions in cells. Analytical Biochemistry 2017, 522 , 10-17.
    29. Vincent S. Shaw, Anthony L. Schilmiller, Harish Vashisth, Richard R. Neubig. Investigating Regulator of G‐protein Signaling (RGS) Protein Dynamics by Hydrogen/Deuterium Exchange. The FASEB Journal 2017, 31 (S1)
    30. B Sjögren. The evolution of regulators of G protein signalling proteins as drug targets – 20 years in the making: IUPHAR Review 21. British Journal of Pharmacology 2017, 174 (6) , 427-437.
    31. Isaac J. Dripps, Qin Wang, Richard R. Neubig, Kenner C. Rice, John R. Traynor, Emily M. Jutkiewicz. The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors. Psychopharmacology 2017, 234 (1) , 29-39.
    32. Atilgan Yilmaz, Chandramohan Kattamuri, Rana N. Ozdeslik, Carolyn Schmiedel, Sarah Mentzer, Christoph Schorl, Elena Oancea, Thomas B. Thompson, Justin R. Fallon. MuSK is a BMP co-receptor that shapes BMP responses and calcium signaling in muscle cells. Science Signaling 2016, 9 (444)
    33. B. Sjogren, S. Parra, K. B. Atkins, B. Karaj, R. R. Neubig. Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury. Journal of Pharmacology and Experimental Therapeutics 2016, 357 (2) , 311-319.
    34. Andrew Tinker, Malcom Finlay, Muriel Nobles, Aaisha Opel. The contribution of pathways initiated via the Gq\11 G-protein family to atrial fibrillation. Pharmacological Research 2016, 105 , 54-61.
    35. Zhihui Xie, Eunice C. Chan, Kirk M. Druey. R4 Regulator of G Protein Signaling (RGS) Proteins in Inflammation and Immunity. The AAPS Journal 2016, 18 (2) , 294-304.
    36. Kyle J. Gerber, Katherine E. Squires, John R. Hepler. Roles for Regulator of G Protein Signaling Proteins in Synaptic Signaling and Plasticity. Molecular Pharmacology 2016, 89 (2) , 273-286.
    37. Kenneth A. Jacobson. New paradigms in GPCR drug discovery. Biochemical Pharmacology 2015, 98 (4) , 541-555.
    38. Eugene L. Piatnitski Chekler, Jessica A. Pellegrino, Thomas A. Lanz, R. Aldrin Denny, Andrew C. Flick, Jotham Coe, Jonathan Langille, Arindrajit Basak, Shenping Liu, Ingrid A. Stock, Parag Sahasrabudhe, Paul D. Bonin, Kevin Lee, Mathew T. Pletcher, Lyn H. Jones. Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities. Chemistry & Biology 2015, 22 (12) , 1588-1596.
    39. Weixing Shen, Joshua L. Plotkin, Veronica Francardo, Wai Kin D. Ko, Zhong Xie, Qin Li, Tim Fieblinger, Jürgen Wess, Richard R. Neubig, Craig W. Lindsley, P. Jeffrey Conn, Paul Greengard, Erwan Bezard, M. Angela Cenci, D. James Surmeier. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron 2015, 88 (4) , 762-773.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect